Despite advances in techniques used in surgery and radiation therapy, there are considerable unmet medical needs in the treatment of patients with Cushing disease. The development of new therapeutic agents is eagerly anticipated and might eventually lead to paradigm shifts in managing patients with this challenging condition. Furthermore, pharmaceutical companies, such as Corcept Therapeutics, Strongbridge Biopharma, AstraZeneca, and others, are actively working toward the development of potential therapies to fulfill the unmet medical needs of the currently used therapeutics.
DelveInsight’s “Cushing’s Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cushing’s Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Cushing’s Syndrome market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Cushing’s Syndrome: An Overview
Cushing’s Syndrome (CS) is a disorder that occurs when the body makes too much of the hormone cortisol over a long period. Cortisol is sometimes called the “stress hormone” because it helps the body respond to stress.
The most common cause of CS is the long-term, high-dose use of cortisol-like glucocorticoids. These medicines are used to treat other medical conditions, such as asthma, rheumatoid arthritis, and lupus. Other people develop endogenous Cushing’s syndrome because their bodies make too much cortisol. Several types of tumors can cause the body to make excess cortisol, such as Pituitary tumors, Ectopic ACTH-producing tumors, and Adrenal tumors. Treatment of CS depends on the underlying cause of excess cortisol but may perhaps include surgery, radiation, chemotherapy, or the use of cortisol-inhibiting drugs.
Cushing’s Syndrome Market Key Facts
According to the Orphanet, the prevalence of endogenous Cushing’s Syndrome (CS) is 1/26,000, and in the EU, it has an annual prevalence of 1/1,400,000-1/400,000, with a peak prevalence at 25–40 years of age.
According to the “National Organization for Rare Disorders,” Cushing syndrome, caused by either an adrenal or pituitary tumor, affects females five times more frequently than males. Symptoms commonly begin between 25 and 40 years of age. Men are affected 3 times more than women by ectopic ACTH production caused by lung cancer, which occurs later in life.
According to the American Association of Neurological Surgeons, an estimated 10-15 per million people are affected with Cushing’s Syndrome yearly. Pituitary adenomas (Cushing’s disease) account for more than 70 percent of cases in adults and about 60-70 percent of cases in children and adolescents. Cushing’s syndrome most commonly affects adults ages 20-50 and is more prevalent in females, accounting for about 70 percent of all cases.
As per the National Organization for Rare Disorders, it is reported that the incidence of endogenous Cushing syndrome is approximately 13 per million people annually.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Cushing’s Syndrome market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Cushing’s Syndrome market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Cushing’s Syndrome Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Cushing’s Syndrome Epidemiology, Segmented as –
Total Prevalent Cases of Cushing’s Syndrome in the 7MM (2019–2032)
Sub-type-specific Prevalence of Cushing’s Syndrome in the 7MM (2019–2032)
Age-specific Prevalence of Cushing’s Syndrome in the 7MM (2019–2032)
Gender-Specific Prevalence of Cushing’s Syndrome in the 7MM (2019–2032)
Diagnosed and Treatable Cases of Cushing’s Syndrome in the 7MM (2019–2032)
Cushing’s Syndrome Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Cushing’s Syndrome market or expected to be launched during the study period. The analysis covers Cushing’s Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers Cushing’s Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Cushing’s Syndrome Market Will Evolve and Grow by 2032 @
Cushing’s Syndrome Therapeutics Analysis
Cushing’s Syndrome (CS) treatment depends on the cause and may include surgery, radiation, chemotherapy, or cortisol-reducing medicines. If the cause is long-term use of glucocorticoids to treat another disorder, the doctor will gradually reduce the dosage to the lowest dose to control that disorder. Sometimes disorders can be treated with a non-glucocorticoid medicine instead. The treatments for Cushing’s Syndrome depend on the specific reason for excess cortisol and may include surgery, radiation, chemotherapy, or the use of cortisol-inhibiting drugs. Drugs that are approved for treating Cushing’s syndrome include mifepristone (Korlym) and pasireotide (Signifor).
Several major pharma and biotech giants are developing therapies for Cushing Syndrome. Currently, Corcept Therapeutics is leading the therapeutics market with its Cushing Syndrome drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Cushing Syndrome Therapeutics Market Include:
And Many Others
Cushing Syndrome Emerging and Marketed Drugs Covered in the Report Include:
CRN-04894: Crinetics Pharmaceuticals
Recorlev: Strongbridge Biopharma
Relacorilant: Corcept Therapeutics
SPI-62: Sparrow Pharmaceuticals
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cushing’s Syndrome Competitive Intelligence Analysis
4. Cushing’s Syndrome Market Overview at a Glance
5. Cushing’s Syndrome Disease Background and Overview
6. Cushing’s Syndrome Patient Journey
7. Cushing’s Syndrome Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Cushing’s Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Cushing’s Syndrome Unmet Needs
10. Key Endpoints of Cushing’s Syndrome Treatment
11. Cushing’s Syndrome Marketed Products
12. Cushing’s Syndrome Emerging Drugs and Latest Therapeutic Advances
13. Cushing’s Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Cushing’s Syndrome Market Outlook (In US, EU5, and Japan)
16. Cushing’s Syndrome Access and Reimbursement Overview
17. KOL Views on the Cushing’s Syndrome Market
18. Cushing’s Syndrome Market Drivers
19. Cushing’s Syndrome Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Strategies
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States